Psoriasis  >>  Ozespa (briakinumab)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ozespa (briakinumab) / AbbVie
NCT00691964: Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Completed
3
347
US
ABT-874, etanercept, placebo
AbbVie (prior sponsor, Abbott), Paragon Biomedical
Plaque Psoriasis
03/09
03/09
NCT00710580: Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Completed
3
350
US
ABT-874, etanercept, placebo
AbbVie (prior sponsor, Abbott), Paragon Biomedical
Moderate to Severe Plaque Psoriasis
04/09
04/09
NCT00570986: A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Completed
3
1465
US, Canada
Placebo, ABT-874
AbbVie (prior sponsor, Abbott)
Plaque Psoriasis
06/09
06/09
NCT00679731 / 2007-004687-47: A Study of Safety and Efficacy Comparing ABT-874 Versus Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis

Checkmark Data (AAD, Extension trial)
Mar 2012 - Mar 2012: Data (AAD, Extension trial)
Completed
3
317
Canada, Europe
ABT-874, Methotrexate
AbbVie (prior sponsor, Abbott)
Psoriasis
11/09
11/09
NCT00626002 / 2007-005955-40: Open Label Continuation Study in Moderate to Severe Psoriasis

Checkmark Data-AAD
Mar 2012 - Mar 2012: Data-AAD
Completed
3
2301
US, Canada, Europe
ABT-874, briakinumab
AbbVie (prior sponsor, Abbott)
Moderate to Severe Plaque Psoriasis
10/11
10/11

Download Options